Optimising TREATment for Severe Gram-Negative Bacterial Infections

计划入组 600 人 · 首次发布于 2025 年 6 月 4 日

Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections

计划入组 810 人 · 首次发布于 2023 年 7 月 12 日

Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria

计划入组 100 人 · 首次发布于 2014 年 12 月 31 日

antibiotics (Gram-positive bacterial infections)

BamA inhibitor (gram-negative bacterial infection)

beta-lactamase inhibitors (gram negative bacterial infection)

Spero Therapeutics

United States

Infant Bacterial Therapeutics AB

Sweden

Armata Pharmaceuticals

United States

Centauri Therapeutics Demonstrates Novel Immunotherapy Approach Against Multi-Drug Resistant Gram-Negative Infections

Blacksmith Medicines Advances Novel Antibiotic FG-2101 Targeting Drug-Resistant Gram-Negative Bacteria

Flightpath Biosciences Licenses Microbiome-Sparing Antibiotic Lolamicin for Gram-Negative Bacterial Infections